| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754274 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 7 Pages |
Abstract
The combination of vorinostat and bortezomib is active in patients with multiple myeloma refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (ClinicalTrials.gov identifier, NCT00773838).
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
David S. Siegel, Meletios Dimopoulos, Sundar Jagannath, Hartmut Goldschmidt, Simon Durrant, Jonathan L. Kaufman, Xavier Leleu, Arnon Nagler, Fritz Offner, Thorsten Graef, Joseph E. Eid, Jennifer Houp, Christine Gause, Scott Vuocolo, Kenneth C. Anderson,